Results of Treatment with Continuous Subcutaneous Insulin Infusion (CSII) in Insulin-Dependent (Type I) Diabetics

W. Felsing; H. Bibergeil; R. Menzel; G. Albrecht; U. Felsing; J. Dabels; G. Reichel; C. Lüder

doi:10.1055/s-0029-1210322

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 1984; 83(2): 136-142
DOI: 10.1055/s-0029-1210322

Original

Results of Treatment with Continuous Subcutaneous Insulin Infusion (CSII) in Insulin-Dependent (Type I) Diabetics

W. Felsing¹ , H. Bibergeil¹ , R. Menzel¹ , G. Albrecht¹ , U. Felsing¹ , J. Dabels² , G. Reichel³ , C. Lüder¹

¹Central Institute of Diabetes “Gerhardt Katsch” Karlsburg
²Department of Internal Medicine, Wilhelm Pieck University Rostock
³Department of Neurology, Ernst Moritz Arndt University Greifswald/GDR

Abstract

PDF Download

Summary

10 labile insulin-dependent diabetic patients treated with CSII were followed up for 6 to 16 months under conditions of everyday life. The mean blood glucose (MBG), glycosylated haemoglobin (HbA₁), motor nerve conduction velocity (MCV), and respiratory heart arrhythmia at rest (RHA) were investigated. A significant improvement of metabolic control was observed (MBG 8.03 ± 1.40 vs 5.18 ± 0.87 mmol/1, p < 0.01; HbA₁ 10.7 ± 1.3 vs 8.7 ± 1.6%, p < 0.05) in comparison with the control values under intensified conventional therapy. MCV increased gradually but the average RHA remained unchanged. The psychological examination employing a questionnaire reflects that all patients selected were highly motivated and that their positive attitudes were further stabilized during pump treatment. An average of three mild hypoglycaemic episodes occurred per month per patient; these were no more than under intensified conventional treatment. Other minor clinical and technical complications occurred at a total frequency of one per month per patient and did not achieve therapeutical relevance.

Key words

Type I diabetes - continuous insulin infusion - diabetic neuropathy

PDF (90 kb)